• Vaccine Name: Cancer Subunit GV1001 Protein Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011507
• Type: Subunit vaccine
• Status: Clinical trial
• TERT gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001294
  • Description: Granulocyte–macrophage colony-stimulating factor (Bernhardt et al., 2006).
• Immunization Route: Intradermal injection (i.d.)

Human Response

• Vaccination Protocol: Forty-eight treatment naive patients with non-resectable, histologially confirmed adenocarcinoma of the pancreas were enrolled in the study (September 2000–March 2003). he vaccine was administered by intradermal (i.d.) injection in the right para-umbilical area following the schedule; three injections in week 1and one weekly injection in weeks 2, 3, 4, 6, and 10. The three different doses of vaccine administered were; low dose: 60 nmole (112 μg) GV1001 in 0.10 ml saline, intermediate dose: 300 nmole (560 μg) GV1001 in 0.125 ml saline, and high dose: 1.0 μmole (1.87 mg) GV1001 in 0.20 ml saline. From 5 to 15 min before each vaccine injection, 30 μg granulocyte–macrophage colony-stimulating factor in 0.10 ml saline was injected i.d. at the vaccination site (Bernhardt et al., 2006).
• Immune Response: Overall, a vaccine related immune response was detected in 63% of the evaluable study population (Bernhardt et al., 2006).
• Efficacy: Median survival for the intermediate dose-group was 8.6 months, significantly longer for the low- (P = 0.006) and high-dose groups (P = 0.05). One-year survival for the evaluable patients in the intermediate dose group was 25% (Bernhardt et al., 2006).